PTC Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
PTC Therapeutics (PTCT) Tops Q2 EPS by 13c; Offers FY16 Outlook
August 4, 2016 5:10 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.14), $0.13 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $15.6 million versus the consensus estimate of $14.68 million.
2016 Guidance:
Total ex-U.S. Translarna nmDMD revenues for 2016 are anticipated to... More